Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Busulfan with 400 Centigray of Total Body Irradiation and Higher dose Fludarabine. An alternative regimen for Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia.
  • +5
  • Jaspreet Gharial,
  • Gregory Guilcher,
  • Tony Truong,
  • Ravi Shah,
  • Sunil Desai,
  • Marta Rojas-Vasquez,
  • Shahbal Kangarloo,
  • Victor Lewis
Jaspreet Gharial
Alberta Children's Hospital

Corresponding Author:[email protected]

Author Profile
Gregory Guilcher
Alberta Children's Hospital
Author Profile
Tony Truong
Alberta Children's Hospital
Author Profile
Ravi Shah
Alberta Children's Hospital
Author Profile
Sunil Desai
Stollery Children's Hospital
Author Profile
Marta Rojas-Vasquez
Stollery Children's Hospital
Author Profile
Shahbal Kangarloo
Tom Baker Cancer Centre
Author Profile
Victor Lewis
Alberta Children's Hospital
Author Profile

Abstract

Background Hematopoietic stem cell transplantation can be curative for children with difficult to treat leukemia. The conditioning regimen utilised is known to influence outcomes. We report outcomes of the conditioning regimen used at the Alberta Children’s Hospital, consisting of busulfan (with pharmacokinetic target of 3750μmol*min/day +/-10%) for 4 days, higher dose (250 mg/m2) fludarabine and 400 centigray of total body irradiation. Procedure This retrospective study involved children receiving transplant for acute lymphoblastic leukemia (ALL). It compared children who fell within the target range for busulfan with those who were either not measured or were measured and fell outside this range. All other treatment factors were identical. Results Twenty-nine children (17 within target) were evaluated. All subjects engrafted neutrophils with a median (IQR) time of 14 days (8-30 days). The cumulative incidence of acute graft versus host disease was 44.8% (95% CI 35.6 – 54.0%), while chronic graft versus host disease was noted in 16.0% (95% CI 8.7% - 23.3%). At two years, the overall survival was 78.1% (95% CI 70.8% - 86.4%) and event free survival was 74.7% (95% CI 66.4% - 83.0%). Cumulative incidence of relapse was 11.3% (95% CI 5.1% - 17.5%). There were no statistically significant differences in between the group that received targeted busulfan compared with the untargeted group. Conclusion The current regimen used in children with ALL results in outcomes comparable to standard treatment with acceptable toxicities and significant reduction in radiation dose. Targeting Busulfan dose in this cohort did not result in improved outcomes.
18 Aug 2023Submitted to Pediatric Blood & Cancer
18 Aug 2023Submission Checks Completed
18 Aug 2023Assigned to Editor
04 Sep 2023Review(s) Completed, Editorial Evaluation Pending
04 Sep 2023Reviewer(s) Assigned
25 Sep 2023Editorial Decision: Revise Minor